Latest news
25 items- PRNAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular CarcinomaSARASOTA, Fla. and MIAMI, Oct. 24, 2024 (GLOBE NEWSWIRE) -- NAYA Biosciences ("NAYA") (NASDAQ:NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and fertility, today announced an update regarding its clinic trial plans. The Company received regulatory approval from the Israeli Ministry of Health in July 2024 and subsequent institutional review board clearance to initiate patient enrollment in up to 7 academic centers for its clinical trial evaluating the safety and efficacy of NY-303, its GPC3-targeting NK Engager bispecific antibody, as a monotherapy for the treatment of hepatocellular carcinoma in patients n
- SECSEC Form RW filed by INVO BioScience Inc.RW - NAYA Biosciences, Inc. (0001417926) (Filer)
- PRINVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA BiosciencesSARASOTA, Fla. and MIAMI, Oct. 21, 2024 (GLOBE NEWSWIRE) -- INVO Biosciences (NASDAQ:INVO), a company focused on expanding its portfolio of clinical and commercial-stage assets in fertility, oncology, and autoimmune diseases through the merger of INVO Biosciences and NAYA Biosciences, today confirmed it has changed its corporate name to NAYA Biosciences Inc. and will begin trading under the new symbol "NAYA" at the market open on Tuesday, October 22, 2024. The CUSIP number for the Company's common stock will remain unchanged. The name and symbol change follows the Company's recent announcement on October 14th regarding the completion of its merger with NAYA Biosciences. The newly combine
- SECINVO BioScience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Leadership Update, Other Events, Financial Statements and Exhibits8-K - INVO Bioscience, Inc. (0001417926) (Filer)
- PRINVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)SARASOTA, Fla. and MIAMI, Oct. 14, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience ("INVO") (NASDAQ:INVO) today announced it has closed its merger with NAYA Biosciences, a company dedicated to increasing patient access to breakthrough treatments in oncology and autoimmune diseases. The combined company expects to change its name to NAYA Biosciences and trade on the NASDAQ under the "NAYA" ticker. The combined company will continue to operate the revenue-generating fertility business as well as expand its focus to the development of first-in-class clinical-stage assets in oncology and autoimmune diseases. The combined company will be led by INVO Chief Executive Officer Steve Shum, INVO Chief Fina
- SECINVO BioScience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - INVO Bioscience, Inc. (0001417926) (Filer)
- SECINVO BioScience Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Financial Statements and Exhibits8-K - INVO Bioscience, Inc. (0001417926) (Filer)
- SECINVO BioScience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - INVO Bioscience, Inc. (0001417926) (Filer)
- SECINVO BioScience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - INVO Bioscience, Inc. (0001417926) (Filer)
- SECSEC Form 10-Q filed by INVO BioScience Inc.10-Q - INVO Bioscience, Inc. (0001417926) (Filer)
- PRINVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDASARASOTA, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment and acquisition of fertility clinics, and with the intravaginal culture ("IVC") procedure enabled by its INVOcell® medical device, today announced financial results for the second quarter 2024 for the period ended June 30, 2024 and provided a business update. Q2 2024 Financial Highlights (all metrics compared to Q2 2023 unless otherwise noted) Revenue was $1,836,597, an increase of 481% compared to $315,902. Revenue increased 17% sequentially compared to Q1 2024.
- SECINVO BioScience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - INVO Bioscience, Inc. (0001417926) (Filer)
- NEWSInvo Bioscience Says On June 18, 2024, Co Received Notice From Nasdaq Informing Co Was Granted Request For Continued Listing On Nasdaq-SEC Filing
- SECINVO BioScience Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits8-K - INVO Bioscience, Inc. (0001417926) (Filer)
- SECSEC Form S-3 filed by INVO BioScience Inc.S-3 - INVO Bioscience, Inc. (0001417926) (Filer)
- NEWSINNO BioScience shares are trading higher after the company reported a year-over-year increase in Q1 EPS results.
- SECINVO BioScience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - INVO Bioscience, Inc. (0001417926) (Filer)
- NEWSINVO Bioscience Q1 EPS $(0.42), Sales $1.58M Up From $348.02K YoYINVO Bioscience (NASDAQ:INVO) reported quarterly losses of $(0.42) per share. The company reported $1.58 million in sales this quarter. This is a 352.84 percent increase over sales of $348.02 thousand the same period last year.
- NEWS12 Health Care Stocks Moving In Wednesday's After-Market SessionGainers SINTX Techs (NASDAQ:SINT) shares increased by 22.2% to $0.16 during Wednesday's after-market session. The company's market cap stands at $19.1 million. As per the news, the Q1 earnings report came out 2 days ago. Petros Pharma (NASDAQ:PTPI) shares rose 12.85% to $0.58. The market value of their outstanding shares is at $4.0 million. Bluejay Diagnostics (NASDAQ:BJDX) shares increased by 10.22% to $0.58. The market value of their outstanding shares is at $1.5 million. INVO Bioscience (NASDAQ:INVO) stock rose 7.47% to $1.15. The market value of their outstanding shares is at $4.3 million. Scorpius Holdings (AMEX:SCPX) shares moved upwards by 7.2% to $0.08. The market value of their
- NEWSPeering Into INVO Bioscience's Recent Short InterestINVO Bioscience's (NYSE:INVO) short percent of float has risen 39.13% since its last report. The company recently reported that it has 17 thousand shares sold short, which is 0.64% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest
- PRINVO Reports Record First Quarter 2024 Financial ResultsSARASOTA, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide through the establishment and acquisition of fertility clinics, and with the intravaginal culture ("IVC") procedure enabled by its INVOcell® medical device, today announced financial results for the first quarter of 2024 and provided a business update. Q1 2024 Financial Highlights (all metrics compared to Q1 2023 unless otherwise noted) Revenue was $1,576,286, an increase of 353% compared to $348,025.Clinic revenue increased 417% to $1,537,199, compared to $297,381. All reported
- SECSEC Form 10-Q filed by INVO BioScience Inc.10-Q - INVO Bioscience, Inc. (0001417926) (Filer)
- NEWSWhy Alibaba Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionShares of Alibaba Group Holding Limited (NYSE:BABA) fell sharply during Tuesday's session following mixed first-quarter financial results. The e-commerce giant reported fiscal fourth-quarter 2023 revenue growth of 7% year-on-year to $30.73 billion, beating the analyst consensus estimate of $30.40 billion. Adjusted earnings per ADS of $1.40 missed the analyst consensus estimate of $1.41, according to data from Benzinga Pro. Alibaba Group shares tumbled 6.8% to $78.86 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Cheetah Net Supply Chain Service Inc. (NASDAQ:CTNT) shares jumped 352.4% to $5.34 as the company reported pricing of $8.19 million
- NEWSWhy Alcon Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving PremarketShares of Alcon Inc. (NYSE:ALC) rose sharply in today's pre-market trading following better-than-expected first-quarter earnings. Alcon posted adjusted earnings of 78 cents per share, beating market expectations of 63 cents per share. The company's quarterly sales came in at $2.444 billion versus estimates of $2.462 billion, according to data from Benzinga Pro. Alcon shares jumped 10.8% to $89.40 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers GameStop Corp. (NYSE:GME) gained 40.2% to $42.70 in pre-market trading after jumping over 74% on Monday. Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) gained 39.2% to $0.08
- SECINVO BioScience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - INVO Bioscience, Inc. (0001417926) (Filer)
INVO FAQ
6 questionsWhat does INVO BioScience Inc. do?
INVO Bioscience, Inc., a medical device company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a patented intravaginal culture system used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development. The company was founded in 2007 and is based in Sarasota, Massachusetts.Where does INVO stock trade?
INVO BioScience Inc. (INVO) is listed on NASDAQ.What sector and industry is INVO in?
INVO BioScience Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about INVO?
INVO BioScience Inc. has had 2 recent analyst actions on file. The most recent action was from Maxim Group: Buy with a $700.00 price target on 2022-01-19. Recent price targets range from $525.00 to $700.00.What companies are similar to INVO?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare INVO side-by-side with any of them on Quantisnow.How can I track INVO on Quantisnow?
Quantisnow aggregates INVO BioScience Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INVO to receive live email and push alerts on every new disclosure.